Topic Archives: Merck (MRK)

I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]

Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]

[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends.  He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]

This is a combo you don’t hear about very often, “founded in the 17th century” and “cancer killing blockbuster” … usually, the little biotechs that newsletters drop hints about are tiny, young, risky, sometimes fly-by-night outfits that are betting it all on a clinical breakthrough. Not this time, apparently. So that’s why my eye was […]

[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]

[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He choses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Enjoy!] In his smoky baritone, singer Stuart Staples of British midlands musical act Tindersticks is bemoaning how he suspects the woman he […]

[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]

[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]

[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars!  You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions.] If you get infected with CRE in your blood, your lungs, your urine, or your biliary system, what is your chance of […]

[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He chooses his own topics, and his words and opinions are his own.] Careful analysis of Ebola sequences in infected Africans confirms this: the entire present Ebola outbreak emerged as a consequence of one boy in Meliandoua, in eastern Guinea, eating a […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

[Ed. note: Today we have another article from Jim Skelton, the Blind Squirrel, who is sharing his experiences as a financial advisor with us. He has agreed to our trading restrictions, the opinions he expresses are his own, and we haven’t reviewed, approved or screened his ideas. His previous articles can be seen here.]  Hello, fellow […]

Comments

  • #Biotech Best turnaround M&A $ARQL 20X $MRK BO in 2yr $ARRY $2s Multiple setbacks ➡️ 20X $PFE BO in 3yr $ECYT...

  • Good work! Elfenbein appears to have missed the first cycle move on CTST, but might be close on the entry for the next o...

  • Merck (MRK) Keytruda/Chemo combo getting a lot of attention at ESMO. https://endpts.com/esmo-roundup-immune-design-roll...

  • $MRK - breaking Merck snaps up a German immuno-oncology upstart in a $603M bolt-on deal Munich-based Rigontec is d...

  • $ESPR (of high relevance) $MRK $CETP Merck hits a bloop single in an epic PhIII CETP cardio contest. Now what? (Endpo...

  • $ESPR $MRK #CETP #CVOT Merck Provides Update on REVEAL Outcomes Study of Anacetrapib Business Wire Business WireJu...

  • Should bode well for $NTRP Long $NTRP Merck $MRK announced late Tuesday that it is shuttering its EPOCH trial for ...

  • Dear KSS. Since Merck ($MRK) settled with Bristol Meyer ($BMY) Friday regarding anti-PD-1 antibodies has this set a prec...

  • $INCY $MRK: Shares of Incyte ($INCY) soared Monday on the heels of news that the company and Merck ($MRK) will condu...

  • Merck (MRK) with good news. http://www.marketwatch.com/story/merck-beats-profit-expectations-bumps-up-full-year-guida...

  • I will also clarify that the Merck/ECYT deal was with Merck (MRK), not Merck KGaA (EMD Serono) so they were different co...

  • $ESPR Red Acre Investments · @redacre http://www.twitlonger.com/show/n_1snl7e3 13th Oct 2015 from TwitLonger Thesis...

  • Although I have never understood why Merck $MRK received it, the FDA has yanked Breakthrough Therapy Designation for its...

  • RE:GILD – good news from Barron’s. Long GILD. RBC’s Michael Yee and team think AbbVie’s (ABBV) update on its he...

  • True, there are always expensive companies, but that's 20X estimated earnings for 2017, 30 months into the future. BMY ...

  • Just saw this - another entry in the HCV parade: Jackpot for Idenix Shareholders -- Market TalkMonday 06/09/2014 07:41 ...

  • om and others. Here is the WSJ article. Sorry for the delay. It was sunny in Seattle and you gotta take advantage ...

  • Companies those working on RNA therapeutics, like Fierce Biotech broke the news that the Swiss giant, Novartis (NVS) was...

  • In regards to OPK; Opko Health (OPK), is expecting to announce top-line results from its Phase III trial for rola...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info